Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma

First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations.

AstraZeneca's Tezspire has been recommended for marketing authorisation... | July 25, 2022

Related Keywords

Japan ,Germany ,United States ,United Kingdom ,Italy ,Cambridge ,Cambridgeshire ,France ,Spain ,America ,Lymphopoietin Isoforms ,Astrazeneca Tezspire ,Pneumologie Mainz ,Thoraxklinik Heidelberg ,Stephanie Korn ,Amgen ,Tezspire Summary Of Committee ,Nasdaq ,World Allergy Organization ,Company On Twitter Astrazeneca ,Astrazeneca ,Investor Relations Team ,European Union ,European Medicines Agency ,Global Asthma Network ,Committee For Medicinal Products Human Use ,Airways Of Human Asthmatics In Vivo ,Zeneca Tezspire ,Medicinal Products ,Human Use ,Medicines Agency ,Senior Physician ,Respiratory Medicine ,Executive Vice President ,Therapy Designation ,Priority Review ,Orphan Drug Designation ,Rare Diseases ,Stromal Lymphopoietin Isoforms ,Inflammatory Disorders ,Human Asthmatics In Vivo ,Potential Biomarker ,Severe Refractory ,Tezspire Summary ,Human Use Opinion Available ,Eur Respir ,Global Asthma ,Global Asthma Report ,Possible Explanation ,Explor Res Hypothesis ,Allergy Asthma ,Illness Among Patients ,Severe Asthma ,Managed Care ,Care Respir ,Allergy Organization ,Adolescents With Severe ,Uncontrolled Asthma ,Astrazeneca Plc Stock Exchange ,News ,Information ,Press Release ,First ,End ,Only ,Biologic ,Ecommended ,Or ,Gu ,Approval ,N ,Patients ,Ith ,Evere ,Asthma ,O ,Henotype ,Dr ,Biomarker ,Tezspire ,Gas ,Teen ,Arketing Azn Gb0009895292 ,